A

    APM (APM)

    Official site

    BIOTECHNOLOGY

    $0.70
    +0.01 (+1.10%)

    Last updated: Jul 17, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    100%(4/4)
    Avg Surprise
    +96.84%
    Streak
    4 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Jul 3
    		$N/AN/AN/ABeat-
    Mar 26
    Reported Apr 28
    		$N/AN/AN/ABeat-
    Dec 25
    Reported Jan 22
    		$-0.04N/AN/ABeat+98.3%
    Sep 25
    Reported Dec 18
    		$-0.06N/AN/ABeat-20.0%
    Mar 25
    Reported Apr 28
    		$-0.29$0.00N/AMiss-16.0%
    Sep 24
    Reported Dec 20
    		$-0.50$0.00N/AMiss-6.4%
    Mar 23
    Reported Apr 28
    		$-2.22$0.00N/ABeat-684.2%
    Jun 22
    Reported Sep 30
    		$-0.05N/A+98.33%Beat+78.7%
    Mar 22
    Reported Apr 29
    		$-0.25N/A+92.42%Beat-232.3%
    Jun 21
    Reported Sep 15
    		$-0.47N/A+84.33%Beat-123.8%
    Mar 21
    Reported Apr 19
    		$0.38N/A+112.26%Beat+215.2%
    Dec 20
    Reported Mar 31
    		$-0.23$0.00N/AMiss-126.4%
    Sep 20
    Reported Dec 31
    		$0.19$0.00N/ABeat+214.3%
    Jun 20
    Reported Sep 1
    		$-0.21$0.00N/AMiss+32.3%
    Mar 20
    Reported Apr 29
    		$-0.33$0.00N/AMiss+37.7%
    Dec 19
    Reported Mar 31
    		$-0.10$0.00N/AMiss+33.9%
    Sep 19
    Reported Dec 31
    		$-0.17$0.00N/AMiss+59.7%
    Jun 19
    Reported Sep 9
    		$-0.31$0.00N/AMiss-85.5%
    Mar 19
    Reported Apr 15
    		$-0.53$0.00N/AMiss-438.1%
    Dec 18
    Reported Mar 31
    		$-0.16$0.00N/AMiss-59.2%
    Sep 18
    Reported Dec 4
    		$-0.41$0.00N/AMiss-1424.2%
    Jun 18
    Reported Sep 30
    		$-0.17$0.00N/AMiss-521.2%
    Mar 18
    Reported Jun 30
    		$-0.10$0.00N/AMiss-392.5%
    Dec 17
    Reported Mar 31
    		$-0.10$0.00N/AMiss-392.5%
    Sep 17
    Reported Dec 31
    		$-0.03$0.00N/AMiss-
    Jun 17
    Reported Sep 30
    		$-0.03$0.00N/AMiss-
    Mar 17
    Reported Jun 30
    		$-0.02$0.00N/AMiss-
    Dec 16
    Reported Mar 31
    		$-0.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.78
    SMA 20$0.79
    SMA 50$0.86
    SMA 200$1.08
    EMA 10$0.77
    EMA 20$0.80
    EMA 50$0.84
    EMA 200$1.00

    MACD

    Line: -0.04Signal: -0.03Hist: -0.00

    ADX

    ADX: 19.6+DI: 14.5-DI: 25.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$0.83

    Bollinger Bands

    Upper Band$0.87
    Lower Band$0.71
    %B Position1999%(Upper)
    Band Width-0.07

    RSI (14-Day)

    Neutral
    34.7

    Momentum Oscillators

    Stoch %K51.6
    Stoch %D56.0
    Williams %R-57.1
    ROC (10d)-12.7%
    Momentum-0.10
    CCI (20d)-284.5
    MFI (14d)13.6

    Volatility Measures

    ATR (14d)$0.08(11.3%)
    StdDev (20d)0.04
    Hist Vol65.1%(High)

    Volume Flow

    VWAP$0.68
    OBV569.9M
    AD Line190.7M
    CMF (20d)-0.185

    Volume Metrics

    Avg Vol (20d)62.1K
    Vol Ratio3.1x(High)
    VWMA (20d)$0.74

    Pivot Points

    R3$1.04
    R2$0.94
    R1$0.81
    Pivot Point$0.71
    S1$0.59
    S2$0.49
    S3$0.37

    Advanced Oscillators

    TSI-17.65
    Ultimate Osc50.7
    KST-120.93

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Mar 2025Dec 2024Sep 2024Mar 2024Sep 2023Mar 2023Jun 2022Mar 2022Jun 2021
    Total RevenueN/A$0$0N/A$0$0N/A$431,378$768,427$527,462$-1,254,941$637,784
    Cost of RevenueN/AN/AN/AN/AN/A$255,046$454,606$1.10M$1.31M$1.11M$1.23M$1.23M
    Gross ProfitN/AN/AN/AN/AN/A$-255,000$-455,000$-665,000$-542,000$-585,000$-2,485,661$-589,000
    Operating Expenses$589,631$1.41M$402,768$928,000$-558,599$2.47M$3.54M$5.87M$8.52M$7.87M$28.16M$8.90M
    R&D$91,711$333,504$19,375$156,238$284,466$1.79M$2.61M$2.59M$4.14M$4.01M$22.12M$5.03M
    SG&A$617,198$617,198$411,904$0$445,325$321,833$0$0$6.29M$0$6.37M$0
    Operating Income$-1,414,762$-1,414,762$-402,766$-1,072,000$558,599$-2,869,000$-3,990,000$-6,539,000$-9,058,000$-8,452,000$25.68M$-9,494,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$26,964$49,184$46,529$78,462$1.33M$68,462$27,667$93,478$3,146$0$3.70B$126,101
    Income Before Tax$-927,135$-927,135$-449,295$-1,499,000$-770,347$-2,659,000$2.26M$-6,605,000$-8,795,000$-2,730,000$-9,043$-17,102,000
    Income Tax Expense$0$0$0$0$0$0$-399,000$-1,118,000$2.21M$-845,000$2.21M$-1,021,000
    Net Income$-921,490$-921,490$-441,780$-1,624,000$-919,900$-2,644,000$2.66M$-5,487,000$-7,914,000$-1,885,000$-2,222,963$-16,081,000
    EBITDA$-1,414,762$-1,414,762$-402,766$-1,420,000N/A$-2,335,000$2.74M$-5,841,000$-8,167,000$-2,147,000$-4,316,275,411$-16,379,000
    EBITN/AN/AN/AN/AN/A$-2,590,046$2.29M$-6,511,648$-8,791,804$-2,729,706$-3,698,598,094$-16,975,864
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about APM

    News

    Niki BioSolutions (APM) Form 3 names President & COO, no trades reported

    Niki BioSolutions (APM) has filed a Form 3, identifying Alidad Mireskandari as its new President & Chief Operating Officer. The filing indicates he is an officer but not a ten percent owner, and importantly, reports no insider stock transactions or current share/option holdings for him. This initial statement of beneficial ownership is a regulatory requirement for new insiders.

    Stock Titan•7/29/26•
    Neutral

    Niki BioSolutions (NIKI) director Laura Philips discloses 6,024-share holding

    Laura A. Philips, a director at Niki BioSolutions, Inc. (NIKI), has filed an initial ownership report (Form 3) disclosing a direct beneficial ownership of 6,024 shares of the company's Common Stock. The filing, dated July 20, 2026, establishes this as her baseline position and indicates no buy or sell transactions have occurred. This disclosure was accepted by SEC EDGAR on July 24, 2026.

    Stock Titan•7/25/26•
    Neutral

    Press Release: Aptorum Group Provides Update on DiamiR Biosciences Merger

    Aptorum Group has provided an update regarding its previously announced merger agreement with DiamiR Biosciences, which involves the acquisition of DiamiR through an all-stock transaction. The merger is progressing, with both companies working towards completing the transaction as outlined in their definitive agreement. This update signals continued efforts to integrate DiamiR Biosciences into Aptorum Group, aimed at leveraging their combined strengths, particularly in diagnostics and precision medicine.

    Moomoo•7/16/26•
    Somewhat-Bullish

    Form 6K Aptorum Group Ltd For: 22 June By Investing.com

    This article reports on the filing of Form 6K by Aptorum Group Ltd for June 22. It mentions the company's stock symbol APM and its trading performance, noting a -3.50% change. The content primarily serves as a notice of the regulatory filing and includes various market data and news unrelated to the main subject.

    Investing.com South Africa•6/23/26•
    Neutral

    Form 6K Aptorum Group Ltd For: 22 June By Investing.com

    This article announces the filing of Form 6K by Aptorum Group Ltd for June 22. It is a brief public notification from Investing.com, providing basic information without further details on the content of the Form 6K itself. The article also includes various market data and navigational links.

    Investing.com Canada•6/22/26•
    Neutral

    Frequently Asked Questions About APM

    Does APM pay dividends?
    APM (APM) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In